The global asthma & COPD therapies market was valued at $32.9bn in 2016 and is projected to grow at a CAGR of 5.6% in the first half of the forecast period. The Anti-inflammatory Drugs submarket will be the fastest growing submarket in the first half of the forecast period. This submarket is estimated to grow at a CAGR of 7.6%.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 300-page report you will receive 113 tables and 130 figures – all unavailable elsewhere.
The 300-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope • Global Asthma & COPD Therapies Market forecasts from 2017-2027, further broken down into: – Global Asthma Therapies Market forecasts – Global COPD Therapies Market forecasts
• Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market: – Bronchodilators monotherapy – Anti-inflammatory drugs – Combination drugs
• Revenue forecast for the Bronchodilators monotherapy market by Typeand revenue forecast of the leading drugs: – Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex – Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent, – Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris
• Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs: – Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex – Anti-leukotrienes: Singulair – Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab
• Revenue forecast for the Combination drugs market and the leading drugs: – Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo
• This report provides individual revenue forecasts from 2017-2027 for these regional and national markets: – The US – Japan – EU5: Germany, France, UK, Italy, Spain – BRIC: Brazil, Russia, India, China – Mexico – Other Countries
• This report discusses the leading companies in the global asthma & COPD therapies market: – GSK – Boehringer Ingelheim – AstraZeneca – Novartis – Merck – Roche – Teva
• This report discusses drugs currently in clinical development for treating asthma and COPD.
• This report discusses the SWOT analysis as well as porter’s five forces analysis of the global asthma & COPD therapies market.
Visiongain’s study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Asthma and COPD Therapies Market Overview 1.2 Global Asthma and COPD Therapies Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Key Questions Answered by This Analytical Report 1.6 Who is This Report For? 1.7 Methodology 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies 2.1 The Pharmaceutical Industry: A Very Brief Overview 2.2 Classifying Respiratory Diseases: Obstructive and Restrictive 2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive 2.3 What is Asthma? 2.3.1 Trends in Asthma Prevalence 2.3.2 Pathophysiology of Asthma 2.3.3 Symptoms of Asthma 2.3.4 Causes and Triggers for Asthma 2.3.5 Treatment of Asthma 2.3.6 Guidelines for Asthma Treatment 2.3.7 Drug Treatments for Asthma 2.3.8 Drug Delivery Methods in Asthma 2.4 What is Chronic Obstructive Pulmonary Disease (COPD)? 2.4.1 Trends in COPD Prevalence 2.4.2 Pathophysiology of COPD 2.4.3 Signs and Symptoms of COPD 2.4.4 Treatment of COPD 2.4.5 Drug Treatments for COPD 2.4.6 Guidelines for COPD Treatment 2.5 Major Drug Classes in the Treatment of Asthma and COPD 2.5.1 Bronchodilators 2.5.2 Anti-Inflammatory Drugs 2.5.3 Combination Drugs 2.6 Phases of Clinical Trials 2.7 Scope of this Report
3. Asthma and COPD Therapies: Global Market 2016-2027 3.1 The Global Respiratory Drugs Market by Therapeutic Area 3.2 The Global Asthma and COPD Therapies Market in 2016 3.2.1 Leading Asthma and COPD Therapies 3.2.2 Leading Companies in the Asthma and COPD Therapies Market 3.3 Global Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2016-2027 3.3.1 Global Asthma Therapies Market: Sales Forecast, 2016-2027 3.3.2 Global COPD Therapies Market: Sales Forecast 2016-2027 3.4 Global Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2016-2027 3.5 Combination Drugs Lead the Asthma and COPD Therapies Market 3.6 How Will Segmental Shares Change to 2027 3.6.1 Global Asthma and COPD Therapies Market: Drivers and Restraints 2016-2027 3.7 Asthma and COPD Therapies: Trends and Developments 3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers 3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Bronchodilator Monotherapy Market 2016-2027 4.1 Introduction to Bronchodilator Monotherapy 4.2 The Bronchodilator Monotherapy Market in 2016 4.2.1 Leading Bronchodilators in 2016 4.2.2 Bronchodilator Monotherapy: Market Forecast 2016-2027 4.2.3 How Will Market Shares by Drug Class Change to 2027? 4.3 The Anticholinergics Market 2016-2027 4.3.1 Leading Anticholinergics in 2016 4.3.2 Anticholinergics: Market Forecast 2016-2027 4.3.3 Market Share of Leading Anticholinergics to 2027 4.3.4 Spiriva (tiotropium. Boehringer Ingelheim) 4.3.5 Atrovent (ipratropium, Boehringer Ingelheim) 4.3.6 Eklira/Tudorza/Bretaris (alcidinium, AstraZeneca/Menarini) 4.4 The SABAs Market 2017-2017 4.4.1 Leading SABAs in 2016 4.4.2 SABAs: Market Forecast 2016-2027 4.4.3 Market Share of Leading SABAs to 2027 4.4.4 Ventolin (salbutamol, GSK) 4.4.5 ProAir (salbutamol, Teva) 4.4.6 Proventil (salbutamol, Merck) 4.4.7 Xopenex (levosalbutamol, Dainippon Sumitomo) 4.5 The Long-Acting Beta2-Agonist (LABA) Market 2016-2027 4.5.1 Leading LABAs in 2016 4.5.2 LABAs: Market Forecast 2016-2027 4.5.3 Market Share of Leading LABAs to 2027 4.5.4 Foradil (formoterol, Merck/Novartis) 4.5.5 Brovana (arfomoterol, Dainippon Sumitomo) 4.5.6 Arcapta/Onbrez (indacaterol, Novartis) 4.5.7 Severent (salmeterol, GSK)
5. Anti-inflammatory Drugs Market 2016-2027 5.1 Introduction to Anti-Inflammatory Drugs 5.2 The Anti-Inflammatory Drugs Market in 2016 5.2.1 Leading Anti-Inflammatory Drugs in 2016 5.2.2 Anti-Inflammatory Drugs: Market Forecast 2016-2027 5.2.3 How Will Market Shares by Drug Class Change to 2027? 5.3 The Corticosteroids Market 2016-2027 5.3.1 Leading Corticosteroids in 2016 5.3.2 Corticosteroids: Market Forecast 2016-2027 5.3.3 Market Share of Leading Corticosteroids to 2027 5.3.4 Flixotide/Flovent (fluticasone propionate, GSK) 5.3.5 Pulmicort (budesonide, AstraZeneca) 5.3.6 QVAR (beclometasone, Teva) 5.3.7 Asmanex (mometasone, Merck) 5.4 The Anti-Leukotrienes Market 2016-2027 5.4.1 Leading Anti-Leukotrienes in 2016 5.4.2 Anti-Leukotrienes: Market Forecast 2016-2027 5.4.3 Market Share of Leading Anti-Leukotrienes to 2027 5.4.4 Singulair (montelukast, Merck) 5.5 The Monoclonal Antibodies Market 2016-2027 5.5.1 Monoclonal Antibodies: Market Forecast 2016-2027 5.5.2 Market Share of Leading Monoclonal Antibodies to 2027 5.5.3 Xolair (omalizumab, Novartis/Roche) 5.5.4 Cinquil/Cinquair (reslizumab, Teva) 5.5.5 Nucala (Mepolizumab, GSK) 5.5.6 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin) 5.5.7 Lebrikizumab (RG3637, Roche) 5.5.8 Dupilumab (REGN668, Regeneron/Sanofi)
6. Combination Drugs Market 2016-2027 6.1 Introduction to Combination Drugs 6.1.1 Leading Combination Drugs in 2016 6.1.2 Combination Drugs: Market Forecast 2016-2027 6.1.3 How Will Market Shares by Drug Change to 2027? 6.1.4 Advair/Seretide (fluticasone/salmeterol, GSK) 6.1.5 Symbicort (budesonide/formoterol fumarate, AstraZeneca) 6.1.6 Combivent (ipratropium/salbutamol, Boehringer Ingelheim) 6.1.7 Dulera (formoterol/mometasone, Merck) 6.1.8 Breo/Relvar Ellipta (vilanterol/fluticasone furoate, GSK) 6.2 Recently Launched Combination Drugs
7. Leading National Markets 2016-2027 7.1 Regional Breakdown of the Global Asthma and COPD Therapies Market 7.2 Global Asthma and COPD Therapies Market; Regional Forecasts 2016-2027 7.2.1 How Will Regional Market Shares Change to 2027? 7.2.2 National Breakdown of the Global asthma and COPD Therapies Market 7.2.3 Global Asthma and COPD Therapies Market: National Markets Forecast 2016-2027 7.2.4 How Will National Market Shares Change to 2027? 7.3 The US Asthma and COPD Therapies Market 2016-2027 7.3.1 The US Asthma and COPD Therapies Market Forecast 2016-2027 7.3.2 US Asthma and COPD Therapies Market Trends and Developments 7.4 Japanese Asthma and COPD Therapies Market 2016-2027 7.4.1 Japanese Asthma and COPD Therapies Market Forecast 2016-2027 7.4.2 Japanese Asthma and COPD Therapies Market: Trends and Developments 7.5 EU5 Asthma and COPD Therapies Market 2016-2027 7.5.1 German Asthma and COPD Therapies Market Forecast 2016-2027 7.5.2 French Asthma and COPD Therapies Market Forecast 2016-2027 7.5.3 UK Asthma and COPD Therapies Market Forecast 2016-2027 7.5.4 Italian Asthma and COPD Therapies Market Forecast 2016-2027 7.5.5 Spanish Asthma and COPD Therapies Market Forecast 2016-2027 7.5.6 EU5 Asthma and COPD Therapies Market: Trends and Developments 7.6 BRIC Asthma and COPD Therapies Market 2016-2027 7.6.1 Chinese Asthma and COPD Therapies Market Forecast 2016-2027 7.6.2 Chinese Asthma and COPD Therapies Market: Trends and Developments 7.6.3 Brazilian Asthma and COPD Therapies Market Forecast 2016-2027 7.6.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments 7.6.5 Indian Asthma and COPD Therapies Market Forecast 2016-2027 7.6.6 Indian Asthma and COPD Therapies Market: Trends and Developments 7.6.7 Russian Asthma and COPD Therapies Market Forecast 2016-2027 7.6.8 Russian Asthma and COPD Therapies Market: Trends and Developments 7.7 Mexican Asthma and COPD Therapies Market 2016-2027 7.7.1 Mexican Asthma and COPD Therapies Market Forecast 2016-2027 7.7.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
8. Leading Companies in the Asthma and COPD Therapies Market 8.1 Asthma and COPD Therapies: Increasing Competition 8.2 Leading Companies in Asthma and COPD in 2016 8.3 Leading Companies: Market Forecast 2016-2027 8.4 How Will Leading Companies’ Market Shares Change to 2027? 8.5 GSK 8.5.1 GSK: Asthma and COPD Therapies 8.5.2 GSK: Sales Forecast 2016-2027 8.5.3 GSK: Products in Development 8.5.4 GSK: Recent Developments 8.6 Boehringer Ingelheim 8.6.1 Boehringer Ingelheim: Asthma and COPD Therapies 8.6.2 Boehringer Ingelheim: Sales Forecast 2016-2027 8.6.3 Boehringer Ingelheim: Asthma and COPD Product Development Ceased 8.6.4 Boehringer Ingelheim: Recent Developments 8.7 AstraZeneca 8.7.1 AstraZeneca: Asthma and COPD Therapies 8.7.2 AstraZeneca: Sales Forecast 2016-2027 8.7.3 AstraZeneca: Products in Development 8.7.4 AstraZeneca: Recent Developments 8.8 Merck & Co. (Merck) 8.8.1 Merck: Asthma and COPD Therapies 8.8.2 Merck: Sales Forecast 2016-2027 8.8.3 Merck: Products in Development 8.8.4 Merck: Recent Developments 8.9 Novartis 8.9.1 Novartis: Asthma and COPD Therapies 8.9.2 Novartis: Sales Forecast 2016-2027 8.9.3 Novartis: Products in Development 8.9.4 Novartis: Recent Developments 8.10 Roche 8.10.1 Roche: Asthma and COPD Therapies 8.10.2 Roche: Sales Forecast 2016-2027 8.10.3 Roche: Products in Development 8.11 Teva 8.11.1 Teva: Asthma and COPD Therapies 8.11.2 Teva: Sales Forecast 2016-2027 8.11.3 Teva: Products in Development 8.11.4 Teva: Recent Developments
9. Asthma and COPD Therapies Pipeline Analysis 2016-2027 9.1 A Strong Asthma and COPD Pipeline 9.2 The Bronchodilators Pipeline 9.2.1 Bronchodilators: Phase 3 Pipeline 9.3 The Anti-Inflammatory Drugs Pipeline 9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline 9.4 The Combination Drugs Pipeline 9.4.1 Combination Drugs: Phase 3 Pipeline 9.5 Other Asthma and COPD Drugs Pipeline
10. Qualitative Analysis of the Asthma and COPD Therapies Market 2016-2027 10.1 SWOT Analysis of the Asthma and COPD Therapies Market 10.2 Strengths 10.2.1 Increasing Prevalence and Disease Burden 10.2.2 High Costs of Treatment 10.2.3 The Changing Perception of COPD 10.2.4 Patient Education: Understanding the Severity of Respiratory Disease 10.2.5 Lifecycle Management Strategies to Counter Patent Expiry 10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion 10.2.7 Developments in Diagnostics 10.3 Weaknesses 10.3.1 Under-Diagnosis: the ‘Ghost Population’ 10.3.2 Side-Effects of Drug Classes 10.3.3 Patent Cliff for Devices 10.3.4 Low Patient Adherence 10.3.5 Costing Pressures in both Developed and Emerging Markets 10.4 Opportunities 10.4.1 Patient Phenotyping and Personalised Medicine 10.4.2 A Strong R&D Pipeline 10.4.3 Ultra-Long-Acting Beta2-Agonists 10.4.4 Muscarinic Antagonists and Beta2-Agonists (MABAs) 10.4.5 Monoclonal Antibodies 10.4.6 LAMA/LABA Combinations 10.4.7 Opportunities in Telehealth 10.5 Threats 10.5.1 Patent Expiry and Generic Competition 10.5.2 Pharmacy Benefit Managers and Cost Control 10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD 10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market 10.6.1 Rivalry among Competitors [Medium] 10.6.2 Threat of New Entrants [Medium] 10.6.3 Power of Suppliers [Medium] 10.6.4 Power of Buyers [High] 10.6.5 Threat of Substitutes [Low]
11. Conclusions 11.1 Asthma and COPD Therapies: A Maturing Market 11.2 The Global Asthma and COPD Therapies Market in 2016 11.3 Current Leading Asthma and COPD Therapies Segments 11.3.1 Leading Asthma and COPD Therapies 11.3.2 Leading Asthma and COPD Therapies Companies 11.4 Leading Regional and National Markets 11.5 Global Asthma and COPD Therapies Market Forecast 2016-2027 11.6 The Future of the Asthma and COPD Therapies Market 11.6.1 Growth in Anti-Inflammatory and Combination Drugs 11.6.2 Personalised Medicine 11.6.3 Unmet Needs in Asthma and COPD 11.7 Strategies for Growth in 2016-2027
Appendices Associated Visiongain Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain report evaluation form
List of Tables Table 2.1 Classification of Respiratory Diseases, 2016 Table 2.2 Causes of Asthma, 2016 Table 2.3 Triggers of Asthma, 2016 Table 2.4 Clinical Trial Phases Table 3.1 World Respiratory Drugs Market: Revenues ($m) and Market Shares (%) by Therapeutic Area, 2016 Table 3.2 Top 10 Asthma and COPD Therapies: Revenue ($m) and Market Shares (%), 2016 Table 3.3 World Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 3.4 World Asthma Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 3.5 World COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 3.6 Global Asthma and COPD Therapies Market Forecast: Revenue ($m), AGR (%) and CAGR (%), by Drug Class, 2016-2027 Table 3.7 Market Shares (%) of Leading Asthma and COPD Therapies Market Segments, by Drug Class, 2016, 2021 and 2027 Table 4.1 Bronchodilator Monotherapy Market: Revenues ($m) and Market Shares (%) by Drug Class, 2016 Table 4.2 Leading Bronchodilators: Revenues ($m) and Market Shares (%), 2016 Table 4.3 Bronchodilator Monotherapy Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2016-2027 Table 4.4 Leading Anticholinergics: Revenues ($m) and Market Shares (%), 2016 Table 4.5 Anticholinergics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027 Table 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2016, 2021 and 2027 Table 4.7 Boehringer Ingelheim: Spiriva Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.8 Boehringer Ingelheim: Atrovent Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.9 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.10 Leading SABAs in 2016 Table 4.11 SABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027 Table 4.12 SABAs Market: Market Shares (%) by Drug, 2016, 2021 and 2027 Table 4.13 GSK: Ventolin Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.14 Teva: ProAir Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.15 Merck: Proventil Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.16 Dainippon Sumitomo: Xopenex Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.17 Leading LABAs: Revenues ($m) and Market Shares (%), 2016 Table 4.18 LABAs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027 Table 4.19 Leading LABAs: Market Shares (%) by Drug, 2016, 2021 and 2027 Table 4.20 Merck/Novartis: Foradil Revenue ($m), AGR (%) and CAGR (%),2016-2027 Table 4.21 Dainippon Sumitomo: Brovana Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.22 Novartis: Arcapta/Onbrez Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.23 GSK: Serevent Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2016 Table 5.2 Leading Anti-Inflammatory Drugs: Revenues ($m) and Market Shares (%), 2016 Table 5.3 Anti-Inflammatory Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug Class, 2016-2027 Table 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) and Market Shares (%) by Drug Class, 2021 and 2027 Table 5.5 Leading Corticosteroids: Revenues ($m) and Market Shares (%), 2016 Table 5.6 Corticosteroids Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027 Table 5.7 Corticosteroids Market: Market Share (%) by Drug, 2016, 2021 and 2027 Table 5.8 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2016-2027 Table 5.9 AstraZeneca: Pulmicort Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.10 Teva: QVAR Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.11 Merck: Asmanex Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.12 Leading Anti-Leukotrienes: Revenues ($m) and Market Shares (%), 2016 Table 5.13 Anti-Leukotrienes Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027 Table 5.14 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2016, 2021 and 2027 Table 5.15 Merck: Singulair Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.16 Monoclonal Antibodies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027 Table 5.17 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2016, 2021 and 2027 Table 5.18 Novartis/Roche: Xolair Asthma Indication Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.19 Teva: Cinquil/Cinquair Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.20 GSK: Nucala Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.21 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.22 Roche: Lebrikizumab Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 5.23 Regeneron/Sanofi: Dupilumab Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.1 Leading Combination Drugs: Revenues ($m) and Market Share (%), 2016 Table 6.2 Combination Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), by Drug, 2016-2027 Table 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2016, 2021 and 2027 Table 6.4 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2016-2027 Table 6.5 AstraZeneca: Symbicort Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.6 Boehringer Ingelheim: Combivent Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.7 Merck: Dulera Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 6.8 GSK: Relvar/Breo Revenue ($m), AGR (%) and CAGR (%), 2016-202 Table 7.1 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2016 Table 7.2 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by Region, 2016-2027 Table 7.3 Market Shares (%) of Leading Regional Asthma and COPD Therapies Markets, 2016, 2021 and 2027 Table 7.4 World Asthma and COPD Therapies Market: Revenues ($m) and Market Shares (%) by National Market, 2016 Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027 Table 7.5 World Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027 (continued) Table 7.6 Market Shares (%) of Leading National Asthma and COPD Therapies Markets, 2016, 2021 and 2027 Table 7.7 US Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.8 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.9 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027 Table 7.10 German Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.11 French Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.12 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.13 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.14 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.15 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%) by National Market, 2016-2027 Table 7.16 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.17 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.18 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.19 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 7.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2016-2027 Table 8.1 Leading Asthma and COPD Drug Manufacturers: Asthma and COPD Drugs Revenue ($m), Market Share (%), 2016 Table 8.2 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m) and Market Shares (%), 2021 and 2027 Table 8.4 GSK: Overview, 2016 Table 8.5 GSK: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016 Table 8.6 GSK: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027 Table 8.7 GSK: Asthma and COPD Therapies Pipeline, 2016 Table 8.8 Boehringer Ingelheim: Overview, 2016 Table 8.9 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016 Table 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2016-2027 Table 8.11 AstraZeneca: Overview, 2016 Table 8.12 AstraZeneca: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016 Table 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m), AGR (%) and CAGR (%), by Drug, 2016-2027 Table 8.14 AstraZeneca: Asthma and COPD Therapies Pipeline, 2016 Table 8.15 Merck: Overview, 2016 Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016 Table 8.17 Merck: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027 Table 8.18 Novartis: Overview, 2016 Table 8.19 Novartis: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016 Table 8.20 Novartis: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027 Table 8.21 Novartis: Asthma and COPD Therapies Pipeline, 2016 Table 8.22 Roche: Overview, 2016 Table 8.23 Roche: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027 Table 8.24 Teva: Overview, 2016 Table 8.25 Teva: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2016 Table 8.26 Teva: Asthma and COPD Therapies Revenue ($m), AGR (%), CAGR (%) by Drug, 2016-2027 Table 8.27 Teva: Asthma and COPD Therapies Pipeline, 2016
List of Figures Figure 1.1 Global Asthma and COPD Therapies Market Segmentation Overview, 2016 Figure 2.1 Summary of GINA Guidance for Asthma Treatment, 2016 Figure 2.2 Summary of GOLD Guidance for COPD Treatment, 2016 Figure 3.1 World Respiratory Drugs Market: Revenues ($m) by Therapeutic Area, 2016 Figure 3.2 World Respiratory Drugs Market: Market Shares (%) by Therapeutic Area, 2016 Figure 3.3 Top 10 Asthma and COPD Therapies: Market Shares (%), 2016 Figure 3.4 World Asthma and COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 3.5 World Asthma Therapies Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 3.6 World COPD Therapies Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 3.7 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2016 Figure 3.8 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2021 Figure 3.9 Global Asthma and COPD Therapies Market: Market Shares (%) by Segment, 2027 Figure 3.10 World Asthma and COPD Therapies Market: Drivers and Restraints, 2016-2027 Figure 4.1 Bronchodilator Monotherapy Market: Revenues ($m) by Drug Class, 2016 Figure 4.2 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2021 Figure 4.3 Bronchodilator Monotherapy Market: Market Shares (%) by Drug Class, 2027 Figure 4.4 Bronchodilator Monotherapy Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.5 Anticholinergics Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.6 Anticholinergics Market: Market Shares (%) by Drug, 2016 Figure 4.7 Anticholinergics Market: Market Shares (%) by Drug, 2021 Figure 4.8 Anticholinergics Market: Market Shares (%) by Drug, 2027 Figure 4.9 Boehringer Ingelheim: Spiriva Revenue ($m) and AGR (%), 2016-2027 Figure 4.10 Boehringer Ingelheim: Atrovent Revenue ($m) and AGR (%), 2016-2027 Figure 4.11 AstraZeneca/Menarini: Eklira/Tudorza/Bretaris Revenue ($m) and AGR (%), 2016-2027 Figure 4.12 SABAs Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.13 SABAs Market: Market Shares (%) by Drug, 2016 Figure 4.14 SABAs Market: Market Shares (%) by Drug, 2021 Figure 4.15 SABAs Market: Market Shares (%) by Drug, 2027 Figure 4.16 GSK: Ventolin Revenue ($m) and AGR (%), 2016-2027 Figure 4.17 Teva: ProAir Revenue ($m) and AGR (%), 2016-2027 Figure 4.18 Merck: Proventil Revenue ($m) and AGR (%), 2016-2027 Figure 4.19 Dainippon Sumitomo: Xopenex Revenue ($m) and AGR (%), 2016-2027 Figure 4.20 LABAs Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.21 LABAs Market: Market Shares (%) by Drug, 2016 Figure 4.22 LABAs Market: Market Shares (%) by Drug, 2021 Figure 4.23 LABAs Market: Market Shares (%) by Drug, 2027 Figure 4.24 Merck/Novartis: Foradil Revenue ($m) and AGR (%), 2016-2027 Figure 4.25 Dainippon Sumitomo: Brovana Revenue ($m) and AGR (%), 2016-2027 Figure 4.26 Novartis: Arcapta/Onbrez Revenue ($m) and AGR (%), 2016-2027 Figure 4.27 GSK: Serevent Revenue ($m) and AGR (%), 2016-2027 Figure 5.1 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2016 Figure 5.2 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2016 Figure 5.3 Anti-Inflammatory Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 5.4 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2021 Figure 5.5 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2021 Figure 5.6 Anti-Inflammatory Drugs Market: Revenues ($m) by Drug Class, 2027 Figure 5.7 Anti-Inflammatory Drugs Market: Market Shares (%) by Drug Class, 2027 Figure 5.8 Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 5.9 Corticosteroids Market: Market Share (%) by Drug, 2016 Figure 5.10 Corticosteroids Market: Market Share (%) by Drug, 2021 Figure 5.11 Corticosteroids Market: Market Share (%) by Drug, 2027 Figure 5.12 GSK: Flixotide/Flovent Revenue ($m) and AGR (%), 2016-2027 Figure 5.13 AstraZeneca: Pulmicort Revenue ($m) and AGR (%), 2016-2027 Figure 5.14 Teva: QVAR Revenue ($m) and AGR (%), 2016-2027 Figure 5.15 Merck: Asmanex Revenue ($m) and AGR (%), 2016-2027 Figure 5.16 Anti-Leukotrienes Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 5.17 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2016 Figure 5.18 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2021 Figure 5.19 Anti-Leukotrienes Market: Market Shares (%) by Drug, 2027 Figure 5.20 Merck: Singulair Revenue ($m) and AGR (%), 2016-2027 Figure 5.21 Monoclonal Antibodies Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 5.22 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2021 Figure 5.23 Monoclonal Antibodies Market: Market Shares (%) by Drug, 2027 Figure 5.24 Novartis/Roche: Xolair Asthma Indication Revenue ($m) and AGR (%), 2016-2027 Figure 5.25 Teva: Cinquil/Cinquair Revenue ($m) and AGR (%), 2016-2027 Figure 5.26 GSK: Nucala Revenue ($m) and AGR (%), 2016-2027 Figure 5.27 AstraZeneca/Kyowa Hakko Kirin: Benralizumab Revenue ($m) and AGR (%), 2016-2027 Figure 5.28 Roche: Lebrikizumab Revenue ($m) and AGR (%), 2016-2027 Figure 5.29 Regeneron/Sanofi: Dupilumab Revenue ($m) and AGR (%), 2016-2027 Figure 6.1 Combination Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 6.2 Combination Drugs Market: Market Shares (%) by Drug, 2016 Figure 6.3 Combination Drugs Market: Market Shares (%) by Drug, 2021 Figure 6.4 Combination Drugs Market: Market Shares (%) by Drug, 2027 Figure 6.5 GSK: Advair/Seretide Revenue ($m) and AGR (%), 2016-2027 Figure 6.6 AstraZeneca: Symbicort Revenue ($m) and AGR (%), 2016-2027 Figure 6.7 Boehringer Ingelheim: Combivent Revenue ($m) and AGR (%), 2016-2027 Figure 6.8 Merck: Dulera Revenue ($m) and AGR (%), 2016-2027 Figure 6.9 GSK: Relvar/Breo Revenue ($m) and AGR (%), 2016-2027 Figure 7.1 World Asthma and COPD Therapies Market: Revenues ($m) by Region, 2016 Figure 7.2 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2016 Figure 7.3 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Region, 2016-2027 Figure 7.4 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2021 Figure 7.5 World Asthma and COPD Therapies Market: Market Shares (%) by Region, 2027 Figure 7.6 World Asthma and COPD Therapies Market: Revenues ($m) by National Market, 2016 Figure 7.7 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2016 Figure 7.8 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2021 Figure 7.9 World Asthma and COPD Therapies Market: Market Shares (%) by National Market, 2027 Figure 7.10 US Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.11 Japanese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.12 EU5 Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2016-2027 Figure 7.13 German Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.14 French Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.15 UK Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR(%) and 2016-2027 Figure 7.16 Italian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.17 Spanish Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.18 BRIC Asthma and COPD Therapies Market Forecast: Revenues ($m) by National Market, 2016-2027 Figure 7.19 Chinese Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.20 Brazilian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.21 Indian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.22 Russian Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 7.23 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m) and AGR (%), 2016-2027 Figure 8.1 Leading Asthma and COPD Drug Manufacturers: Revenue ($m), 2016 Figure 8.2 Leading Asthma and COPD Drug Manufacturers: Market Share (%), 2016 Figure 8.3 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2021 Figure 8.4 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2021 Figure 8.5 Leading Asthma and COPD Drug Manufacturers: Revenues ($m), 2027 Figure 8.6 Leading Asthma and COPD Drug Manufacturers: Market Shares (%), 2027 Figure 8.7 GSK: Asthma and COPD Therapies Revenue ($m) by Drug, 2016 Figure 8.8 GSK: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016 Figure 8.9 GSK: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027 Figure 8.10 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) by Drug, 2016 Figure 8.11 Boehringer Ingelheim: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016 Figure 8.12 Boehringer Ingelheim: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027 Figure 8.13 AstraZeneca: Asthma and COPD Therapies Revenue ($m) by Drug, 2016 Figure 8.14 AstraZeneca: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016 Figure 8.15 AstraZeneca: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027 Figure 8.16 Merck: Asthma and COPD Therapies Revenue ($m) by Drug, 2016 Figure 8.17 Merck: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016 Figure 8.18 Merck: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027 Figure 8.19 Novartis: Asthma and COPD Therapies Revenue ($m) by Drug, 2016 Figure 8.20 Novartis: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016 Figure 8.21 Novartis: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027 Figure 8.22 Roche: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027 Figure 8.23 Teva: Asthma and COPD Therapies Revenue ($m) by Drug, 2016 Figure 8.24 Teva: Asthma and COPD Therapies Revenue Share (%) by Drug, 2016 Figure 8.25 Teva: Asthma and COPD Therapies Revenue ($m) and AGR (%), 2016-2027 Figure 10.1 Asthma and COPD Therapies Market: Strengths and Weaknesses, 2016-2027 Figure 10.2 Asthma and COPD Therapies Market: Opportunities and Threats, 2016-2027 Figure 10.3 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market, 2016-2027 Figure 12.1 World Asthma and COPD Therapies Market Forecast: Revenues ($m) by Therapeutic Area, 2016-2027
Organisations Mentioned in the Report American Lung Association Bank of Spain Bundesministerium fur Gesundheit (German Ministry of Health) Brazilian Unified Health System (SUS) Department of Pharmaceuticals (India) European Lung Foundation European Respiratory Foundation European Respiratory Society Federal Commission for the Protection against Sanitary Risk (COFEPRIS) Global Initiative for Asthma (GINA) Global Initiative for Chronic Obstructive Lung Disease (GOLD) Italian Medicines Agency (AIFA) Italian Servicio Sanitario Nazionale (SSN) Japanese Pharmaceuticals and Medical Devices Agency Pan-American Health Organization (PAHO) Seguro Popular (Mexico) UK National Health Service (NHS) US Centers For Disease Control and Prevention (CDC) US Food and Drug Administration (FDA) US Institutes of Health US National Blood, Heart and Lung Institute World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2017-2027
Contract manufacturing represents the largest sector of the pharma outsourcing industry. Pharmaceutical companies have sought to take advantage of the...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
